Nov 09,2023 TOP STORY

Vida Health Announces $28.5 Million in Funding; Appoints Joe Murad CEO

Vida Health today announced it has closed $28.5 million in financing led by existing investors, including General Atlantic, Ally Bridge, Canvas Ventures, Hercules Capital, and other insiders. The company also named Joe Murad as Chief Executive Officer. Murad brings more than two decades of experience leading healthcare technology companies, with a demonstrated ability to guide venture-backed businesses from early stages through phases of significant growth. Murad succeeds Stephanie Tilenius, who will step down following nine years of service as Founder and CEO. Vida intends to use the investment to further scale and pursue ongoing growth opportunities, particularly in the rapidly expanding obesity and diabetes market.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Nov 09,2023 TOP STORY

Vida Health Announces $28.5 Million in Funding; Appoints Joe Murad CEO

Vida Health today announced it has closed $28.5 million in financing led by existing investors, including General Atlantic, Ally Bridge, Canvas Ventures, Hercules Capital, and other insiders. The company also named Joe Murad as Chief Executive Officer. Murad brings more than two decades of experience leading healthcare technology companies, with a demonstrated ability to guide venture-backed businesses from early stages through phases of significant growth. Murad succeeds Stephanie Tilenius, who will step down following nine years of service as Founder and CEO. Vida intends to use the investment to further scale and pursue ongoing growth opportunities, particularly in the rapidly expanding obesity and diabetes market.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Nov 06,2023 TOP STORY

Click Therapeutics Secures $20 Million Debt Financing from HSBC

Click Therapeutics announced that it has closed on a $20 million term loan from HSBC Innovation Banking, a division of HSBC Bank USA, N.A. The term loan was partially drawn at closing, with the proceeds used to retire Click’s previous term loan. Click Therapeutics has announced four major co-development and commercialization collaborations to date for the treatment of major depressive disorder (MDD), schizophrenia, and substance use disorders. Click is also progressing its lead internal program for the preventive treatment of migraine with pivotal data expected in 2024.

FUNDING DEBT FINANCING
View Analyst & Ambassador Comments
Go to original news
Oct 31,2023 TOP STORY

Sugar.fit Raises $11 Mn Funding To Help People Combat Diabetes

Healthtech startup Sugar.fit has raised $11 Mn in Series A funding led by MassMutual Ventures. The round saw participation from existing investors including Cure.fit, Tanglin Venture Partners, and Endiya Partners. The healtech startup will use the fresh capital to expand its product offering, launch an offline presence, and accelerate research and development in the field of diabetes management, stepping up the brand’s footprint and growth. Founded in 2021 by Madan Somasundaram and Shivtosh Kumar, Sugar.fit seeks to manage and reverse Type 2 and pre-diabetes through a holistic, science-backed, and data-driven digital health experience.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Oct 31,2023

Egyptian health tech Almouneer raises $3.6M to scale its platform for treating diabetes and obesity

Almouneer, an Egyptian healthtech company, has raised $3.6 million in seed funding to support the development and expansion of its platform for treating diabetes and obesity. The funding round was led by Dubai-based Global Ventures, with participation from other international investors, including Proparco, Digital Africa via the Bridge Fund, Wrightwood Investments, and others. Almouneer’s platform, DRU, is a patient-centric, digitally-enabled lifestyle and diabetes management platform. It allows patients to upload their medical records, access their latest medical data and current medications, connect with doctors and healthcare personnel via chat or phone, and subscribe to personalised treatment and nutrition plans.

FUNDING SEED ROUND
View Analyst & Ambassador Comments
Go to original news
Oct 24,2023 TOP STORY

Signos Announces Series B Funding Round of $20 Million

Signos, a metabolic health platform that utilizes a unique AI-engine with a continuous glucose monitor (CGM) to offer real-time data and recommendations for healthy weight management, has announced a successful $20 million Series B funding round. The round was led by Cheyenne Ventures and GV (Google Ventures), with additional investments from Dexcom Ventures and Samsung. It will enable Signos to expand its team, extend its platform and conduct further research on metabolic health. The Signos app allows users to log their food intake and exercise levels, enabling the AI platform to learn how an individual’s metabolism responds to various foods and fitness patterns. This information then provides personalized, data-driven recommendations based on an individual’s unique metabolic profile.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Oct 18,2023

Poppins secures €8M for children's neurodevelopmental disorder therapy

Poppins (formerly known as Mila) has announced a €8 million financing round led by Eurazeo alongside Verve Ventures, Allianz France and HEC Ventures. This brings the company's funding to €12.9 million. Founded in 2018 and spun out of the École Polytechnique, the company is dedicated to the treatment of children's neurodevelopmental disorders, launching a therapeutic program for the families of children with specific "dys" learning difficulties, such as dyslexia, dysorthographia and dyscalculia. Poppins has created a digital therapy in the form of a musical video game downloadable to tablets or smartphones that can be used independently at home by children aged 7 to 11 with one or more specific learning disorders. A CE-marked digital medical device, the app is based on five years of scientific research carried out by engineers from the École Polytechnique and doctors and speech therapists from the teams at the La Timone hospital in Marseille, in close collaboration with the Fédération Française des DY.

FUNDING FUNDING ROUND

#mobile app

View Analyst & Ambassador Comments
Go to original news
Nov 25,2021

Medical AI Provider Lunit Raises $61M in Funding Round Led By Major Global Healthcare Investors

Lunit, a leading medical AI provider, today announced it has raised $61 million in its Pre-IPO fundraising round ahead of the company’s planned public offering on the South Korean stock market (KOSDAQ) early next year. A number of new investors have joined the round including leading US healthcare investors HealthQuest Capital, Casdin Capital, and American Cancer Society BrightEdge, as well as Asia-based global healthcare investors Tybourne Capital Management, and NSG Ventures. HealthQuest Capital invested $20 million of the total funding amount. Prior to this latest round, Lunit closed a strategic investment of $26 million from Guardant Health last July. Combined with the pre-IPO round, the company has secured more than $135 million in total to date.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Jan 07,2020

Lunit Secures $26M in Series C Funding Round, Led by Asian Investors

Lunit, a leading medical artificial intelligence (AI) company providing solutions for precision diagnostics and therapeutics, announced today that it has raised $26M in its series C funding. This round was backed by Asian investors, led by Korea’s Shinhan Investment, followed by InterVest, IMM Investment, Kakao Ventures, and China’s Legend Capital of Lenovo Group. The funding round is the latest after the Fujifilm investment of $4.3M and Series B funding of $15M last year. Founded in 2013, Lunit has since raised $50M in total. The added capital will fuel and accelerate the global sales of its AI software for chest and breast radiology, Lunit INSIGHT series. The chest x-ray solution, Lunit INSIGHT CXR, has recently received a CE mark, now cleared for European sales. 

FUNDING SERIES C
View Analyst & Ambassador Comments
Go to original news
Jul 16,2018

AI Healthcare Company Lunit Raises $15 Million in Series B Funding Round

Lunit, an AI healthcare startup company that uses deep-learning technology in medical imaging, today announced its Series B raise of $15 million. The round was led by Intervest, joined by Softbank Ventures, Kakao Ventures, Mirae Asset Venture Investment, KT Investment(Korea Telecom) and others—a total of 7 international venture capital investors. “The investment and support from the investors were key to our development of medical AI and its global recognition,” said Anthony Paek, CEO of Lunit. “We will now accelerate the market release of our developed products and step up to become a company that can help alleviate sufferings of patients and families from various diseases.”

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Subscribe to FUNDING